Genetic deletion of cathepsin S, but not cathepsin X, marginally improved symptoms of colitis, while pharmacological inhibition of cathepsin S by the reversible drug LY3000328 ultimately led to increased cathepsin S and L activity and marginally exacerbated colitis symptoms. Here, CTSS is linked to colitis.